None listed
Conditions
Interventions
Intervention1: HAIRAL7: The study drug Approx 5-10 mL will be applied to the hair roots till hair roots wet. Applied once daily preferably in the night. Total duration of drug product administration i
Sponsors
ABS LABORATORIES
Eligibility
Inclusion criteria
Inclusion criteria: ï?? Males and females of age group 18-40 years ï?? Subjects who are suffering from mild to moderate hair loss and/or Subjects suffering from mild to moderate dandruff. ï?? Subjects who are willing to give written informed consent
Exclusion criteria
Exclusion criteria: ï?? Any dermatological condition of the scalp other than hair loss and /or dandruff. ï?? Prior use of scalp hair growth treatment (e.g., finasteride, minoxidil) within 6 months ï?? Any prior hair growth procedures (e.g., hair transplant or laser) ï?? History of alcohol or drug addiction ï?? History of skin allergy ï?? Regular use of medication which might interfere with the results of the study ï?? Subject had used phytotherapy (e.g., saw palmetto) within eight weeks prior to baseline. ï?? Any active skin infection in the scalp area or scarring in the target area. ï?? Photosensitivity to laser light. ï?? Subjects with psoriasis/seborrheic dermatitis ï?? Medications with anti-androgenic properties (e.g., cyproterone acetate, spironolactone, ketoconazole, flutamide, bicalutamide), topical estrogen, tamoxifen, anabolic steroids, oral glucocorticoids (or other medications at the discretion of the Investigator.(these are the Medications for hair loss) ï?? History of thyroid or other medical condition including polycystic ovary syndrome that might influence hair growth and loss, at the discretion of the Investigator. ï?? Subject had ever received radiation therapy to the scalp, or had chemotherapy within the past year
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Subjective Assessment by patient using diary card evaluation - Assessment of adverse event Timepoint: 4 months | — |
Primary
| Measure | Time frame |
|---|---|
| Primary Efficacy Endpoints: Change in global photographic assessment for hair growth Change in the investigator assessment score for Hair count each visit from enrollment onwards after treating with IP Investigator assessments Reduction in dandruff score for applicable subjects Secondary End points: - Subjective Assessment by patient using diary card evaluation - Assessment of adverse event Timepoint: 4 months | — |
Countries
India
Contacts
Public ContactDr Srinivas C MD
Outcome results
None listed